touchIMMUNOLOGY was delighted to speak with Dr Aurélie Najm (University of Glasgow, Glasgow, UK) about B-cell repertoire changes in patients with rheumatoid arthritis and the recent analysis designed to create a nomogram capable of using B-cell repertoire properties to predict response to methotrexate.
The analysis entitled ‘B Cells Repertoire Repartition Predicts Response to Methotrexate at 6 and 12 Months in Naïve RA: A Machine Learning Driven Approach’ (ABSTRACT NUMBER: 0982) was presented at the ACR Convergence, 5-9 November 2021.
- How does the B cell repertoire change in rheumatoid arthritis according to treatment response? (0:19)
- Could you tell us a little about the machine learning based approach you have developed for predicting response to methotrexate? (1:02)
- What were the aims, design of your study assessing this model? (1:57)
- What were the study findings? (2:50)
- What will be the potential impact of this approach on clinical practice? (4:02)
Disclosures: Dr Aurélie Najm has acted as a consultant for BMS, UCB and Chugai; and as a speaker for UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
Share this Video
Related Videos In Rheumatoid Arthritis
Roy Fleischmann, ACR 2021: Efficacy and Safety of Olokizumab plus Methotrexate in a Placebo and Active Controlled Study
Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) discusses the results from the phase 3, head-to-head, randomized, placebo-controlled clinical trial investigating olokizumab in patients with active rheumatoid arthritis inadequately controlled with methotrexate, with a comparator arm of adalimumab. The abstract entitled ‘Efficacy and Safety of Olokizumab in a Phase III Trial […]
Roy Fleischmann, ACR 2021: Safety and Efficacy of Tofacitinib vs TNF Inhibitors in ORAL Surveillance
It was a pleasure to speak with Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) about ORAL Surveillance (NCT02092467). Mandated by the FDA, due to observed increases in lipids and malignancies in patients with RA treated with tofacitinib, this study was designed to investigate the relative risk of tofacitinib compared to […]
Gilles Boire, ACR 2021: A Mindfulness-Based Program to Improve PROs in patients with Rheumatoid Arthritis
It was a pleasure to discuss with Prof. Gilles Boire (Université de Sherbrooke, Québec, Canada) the recent pilot study in which a Mindfulness-Based Stress Reduction (MBSR) program was offered to patients with controlled rheumatoid arthritis but elevated negative PROs. The abstract entitled ‘Mindfulness-Based Stress Reduction (MBSR) to Improve Patient-Related Outcomes (PROs) in Patients with Rheumatoid […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!